Kaltsa *et al* \[[@ref1]\] reported that human β defensin-1 (hBD-1) is upregulated in cirrhotic patients and might serve as a biomarker of bacterial translocation involved in the pathogenesis of complications including hepatic encephalopathy (HE); dysbiosis of gastrointestinal microbiota, even salivary and gastric *Helicobacter pylori* (*Hp*) and multiple non-*Hp* organisms, is associated with systemic inflammation and complications including HE \[[@ref1]-[@ref3]\].

*Hp* infection (*Hp*-I), strongly associated with viral-related cirrhosis, is more common in cirrhotic patients with HE. *Hp* may be involved in HE and post-HE persistent cognitive dysfunction pathophysiology by releasing proinflammatory and vasoactive substances involved, through blood-brain barrier (BBB) disruption, in brain pathologies; *Hp* might access the brain via the oral-nasal-olfactory pathway or by circulating monocytes (infected with *Hp* due to defective autophagy) through disrupted BBB, leading to neurodegeneration \[[@ref4]-[@ref6]\]. Likewise, human defensins might also contribute to *Hp*-related brain pathophysiology by modulating innate and adaptive immune system responses \[[@ref7]\].

*Hp*-I induces hBD-1 mRNA expression \[[@ref8]\], but develops resistance against hBD-1 \[[@ref9]\]. Moreover, *Hp* might be further involved in the BBB breakdown, by releasing defensins, particularly those that display unique distribution at BBB sites. *Hp* can activate granulocytes and induce defensin release from granulocytes; consequently, defensins, secreted by activated granulocytes, penetrate the BBB, gain access to the brain, thereby possibly contributing to neurodegeneration \[[@ref9]\]. In the brain, HBD-1 expression acts as activator and modulator of innate and adaptive immunity within microglia and astrocytes, cerebral cells critical to the brain neuroinflammatory responses. HBD-1 mRNA expression is significantly increased in the choroid plexus and hippocampus of the neurodegenerative brain; HBD-1 might be of considerable importance early in the neurodegenerative process \[[@ref9]\]. Finally, serum sCD14 levels, mentioned by the authors \[[@ref1]\], are associated with genetic variants in both CD14 promoter and *Hp*-I and consequently with certain disease or diseases outcomes \[[@ref10]\]. However, further studies are needed to elucidate the aforementioned considerations.
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